SCHEMBL256785

SCHEMBL256785

NC(C[N+](=O)[O-])c1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.47
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
NISCH Q9Y2I1 1/20 0.39
CPA1 P15085 3/20 0.37
AOC3 Q16853 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
IDO1 P14902 2/20 0.36
TDO2 P48775 2/20 0.36
IDO2 Q6ZQW0 2/20 0.36
NPC1 O15118 1/20 0.36
ADAM17 P78536 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15206222 0.98 CNR1 (0.46) CNR1ALDH1A1GAANISCHCPA1
SCHEMBL10216737 0.86 PNMT (0.49) CNR1ALDH1A1GAACYP1A2CYP3A4
Hydrochloric Acid SCHEMBL382247 0.85 ALDH1A1 (0.50) CNR1ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6304335 0.79 ADRB2 (0.47) CNR1ALDH1A1GAACPA1AOC3
SCHEMBL27828299 0.79 ADRB2 (0.47) CNR1ALDH1A1GAACPA1AOC3
SCHEMBL27828301 0.79 ADRB2 (0.47) CNR1ALDH1A1GAACPA1AOC3
SCHEMBL10216727 0.76 CNR1 (0.51) CNR1CPA1IDO1TDO2NPC1
Hydrochloric Acid SCHEMBL381653 0.75 CNR1 (0.50) CNR1ALDH1A1CPA1IDO1TDO2
Nitralamine SCHEMBL29387852 0.73 NPSR1 (0.52) CNR1ALDH1A1GAANISCHCYP1A2
SCHEMBL10089992 0.73 LMNA (0.50) CNR1ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9180120-B2 Substituted N-phenethyltriazoloneacetamides and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-11-10 US disclosed
US-9180120-B2 Substituted N-phenethyltriazoloneacetamides and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-11-10 US disclosed
EP-2619188-B1 SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF BAYER IP GMBH (DE) 2015-05-06 EP disclosed
US-20130225646-A1 SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-29 US disclosed
US-20130225646-A1 SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-29 US disclosed
WO-2012028644-A1 SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225646-A1 SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF TNNT2, TNNI3, PNMT CNR1 2989/4885ALDH1A1 2925/4885GAA 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.